Vaxcyte, Inc. (PCVX) is a clinical-stage vaccine developer whose lead asset, the 31-valent pneumococcal conjugate vaccine (PCV) candidate VAX-31, just cleared a pivotal hurdle. With the stock spiking roughly 50% on positive Phase 3 data, investors are asking whether the shares can climb to the average analyst price target of about $110.
This is a stock with extensive coverage, and the $110 figure is the average of the individual analyst price targets reviewed, rounded from a calculated mean near $109.67. The low-to-high range is wide, spanning roughly $67 to $163.
At the bullish end, Mizuho carries a $163 target, and Jefferies' Roger Song called the data a "blue-sky" scenario while maintaining a $146 target. Guggenheim's Seamus Fernandez raised his target to $125 from $116 after the readout, keeping a Buy rating and Top Pick designation. Bank of America trimmed its target to $130 from $133 in late September, while Needham reiterated $110.
More cautious voices sit well below that. Goldman Sachs has a neutral-leaning $67 target, with BTIG near $89, Leerink Partners around $82, and TD Cowen near $75. The disagreement largely reflects different assumptions about how much of the adult pneumococcal market VAX-31 can capture against incumbents from Pfizer and Merck, and how much future equity dilution will weigh on per-share value.
The latest verified price sits around $87 after the OPUS-1 topline readout, versus a prior close near $56. Reaching the $110 target implies a further gain of about 26%, a substantial move for a clinical-stage biotech that has already repriced sharply in a single session.
Unlike a profitable company whose path can be modeled on earnings, Vaxcyte's stock forecast rests almost entirely on clinical and regulatory milestones. VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older, showing noninferiority across shared serotypes and superiority for several unique serotypes. Management now plans a Biologics License Application (BLA) submission in the first half of 2028, with OPUS-2 and OPUS-3 results expected in the first half of 2027.
The clearest support is the quality of the data itself. Analysts described the readout as "near best-case," removing a major de-risking event for the lead program and validating the company's carrier-sparing conjugation platform. VAX-31's broad serotype coverage positions it as a potential best-in-class competitor in an adult pneumococcal vaccine market that analysts describe as worth billions and still growing.
A strong balance sheet, with over $1 billion in cash reported in recent quarters, provides runway through the next clinical and regulatory steps. Upward earnings-estimate revisions and raised targets from firms like Guggenheim signal rising conviction in the commercial opportunity.
Vaxcyte is pre-revenue, generating losses as it funds a broad pipeline, so the valuation is almost entirely forward-looking. Dilution from future capital raises could pressure per-share value, a point reflected in some lower targets. Full safety and immunogenicity details from OPUS-1, as well as the infant studies and the OPUS-2 and OPUS-3 trials, still carry binary risk.
Competition is entrenched: Pfizer's Prevnar 20 and Merck's Capvaxive are marketed products with established commercial infrastructure. Finally, the long runway to a 2028 BLA filing and a launch now expected around 2029 (per BofA's note) leaves substantial execution and regulatory risk that could compress the multiple.
The surge established a new 52-week high near $89, breaking decisively above the prior ceiling around $65. Before the readout, the 50-day moving average sat near $58.67 and the 200-day near $56.18, levels now far below the current price. Mizuho suggested the stock could trade in a $90–$100 range near term, so $100 looms as a psychological resistance level ahead of the $110 target, while the old $65 breakout zone may act as a distant support area on any pullback.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may differ and the company's value drivers extend well beyond that window. Key items to watch include the full OPUS-1 safety and immunogenicity presentation, the OPUS-2 and OPUS-3 readouts expected in the first half of 2027, infant study updates, BLA submission timing, and any further target revisions or financing announcements.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, catalyst-driven name like Vaxcyte, this kind of tool can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals to see how automated insights might fit into your research process.
The $110 target is the average of a wide analyst range, from roughly $67 to $163, and sits about 26% above the post-surge price near $87. The bull case rests on best-in-class VAX-31 data and a large, growing pneumococcal market, while the bear case emphasizes a long path to revenue, entrenched competition, dilution, and a forward-looking valuation. With the stock already repricing sharply, reaching $110 depends less on the headline data and more on successful execution through additional trials, regulatory filing, and eventual commercialization. No outcome is guaranteed, and the wide target range underscores genuine uncertainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PCVX has been loosely correlated with BCYC. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PCVX jumps, then BCYC could also see price increases.
| Ticker / NAME | Correlation To PCVX | 1D Price Change % | ||
|---|---|---|---|---|
| PCVX | 100% | -3.85% | ||
| BCYC - PCVX | 57% Loosely correlated | -2.47% | ||
| VIR - PCVX | 47% Loosely correlated | +1.34% | ||
| NVAX - PCVX | 45% Loosely correlated | -2.90% | ||
| PTGX - PCVX | 44% Loosely correlated | -0.79% | ||
| ABUS - PCVX | 43% Loosely correlated | -0.24% | ||
More | ||||